Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Renalytix Plc (LSE:RENX) Extends Positive Momentum as Healthcare Innovation Strengthens Investor Confidence

Renalytix Plc is a precision diagnostics company focused on improving kidney disease detection through artificial intelligence and biomarker-based testing. The recent improvement in its share price reflects growing optimism surrounding healthcare innovation, supportive clinical developments, and continued investor interest in precision medicine. Demand for …

Ankur Sharma | 31 July 2026

Can Europe's Ageing Population Drive Geratherm Medical's Next Growth Chapter?

Geratherm Medical AG is a German manufacturer of medical technology and devices, with a heritage in clinical thermometry and a broader range spanning respiratory diagnostics, cardiovascular and stroke-risk diagnostics, and patient-warming systems. It is primarily listed in Germany (Frankfurt ticker GME) and appears on …

Ankur Sharma | 31 July 2026

Biophytis and the Biotech Lottery: Breakthrough Hope Meets Micro-Cap Risk

Biophytis SA (visible on the London market under the line 0D1W, and traded as ADSs on Nasdaq under BPTS, with a primary listing in Paris) is a clinical-stage biotechnology company developing drug candidates for age-related diseases. It is, in many respects, the archetype of …

Divya Sood | 31 July 2026

Paion's High-Beta Comeback: Is This Forgotten Healthcare Name Ready to Wake Up?

On paper, Paion AG (historically visible on the London market under the line 0NF3) looks like the kind of forgotten, high-beta healthcare name that speculative investors hunt for: a small drug developer whose shares might, in theory, 'wake up' on good news. Closer verification, …

Divya Sood | 31 July 2026

Halma plc (LSE:HLMA) Jumps as Record Performance, Strategic Acquisitions and Innovation Reinforce Investor Confidence

Halma plc is a global group of technology companies that develops products and services designed to make workplaces safer, improve environmental protection, and enhance healthcare outcomes. Operating across Safety, Environmental & Analysis, and Healthcare sectors, the company has built a long-standing reputation for consistent …

Ankur Sharma | 31 July 2026

Can Keyhole-Surgery Growth Revive Surgical Innovations' Forgotten Shares?

Surgical Innovations Group plc (LSE: SUN) is a UK company that designs, manufactures and supplies instruments and devices used in minimally invasive, or keyhole, surgery. This is a specialist corner of the medical-device industry, and Surgical Innovations is a genuine micro-cap whose shares have …

Ankur Sharma | 31 July 2026

Imunon's Cancer-Therapy Bet: Moonshot Potential or Another Biotech Mirage?

Imunon, Inc. is a US-based, Nasdaq-listed clinical-stage biotechnology company (ticker IMNN) that also appears on London screens under the line 0HUZ. UK investors should recognise it as an American company operating under US regulation, with the London quotation a secondary line. Imunon is developing …

Ankur Sharma | 31 July 2026

TheraCryf's Biotech Gamble: Can One Pipeline Win Transform Its Valuation?

TheraCryf plc (LSE: TCF) is a UK clinical-stage biotechnology company that emerged from the rebranding and repositioning of ReNeuron Group, a business historically associated with stem-cell and regenerative-medicine research. Under its current identity, the company has refocused around a pipeline of therapeutic candidates, seeking …

Ankur Sharma | 31 July 2026

Can Digital Diagnostics Turn Feedback PLC Into a Small-Cap Market Surprise?

Feedback plc (LSE: FDBK) is a UK-listed digital health company whose ambition far exceeds its size. It develops software aimed at improving how clinicians communicate and how patients move through diagnostic pathways, addressing well-documented bottlenecks in the National Health Service. As a micro-cap, its …

Ankur Sharma | 31 July 2026

Soligenix: The Tiny Drug Developer Offering Binary Upside—and Brutal Risk

Soligenix, Inc. is a US-based, Nasdaq-listed biopharmaceutical company (ticker SNGX) that also appears on London screens under the line 0A6I. Investors encountering it via a UK screener should understand that it is an American company whose primary regulatory and disclosure framework is that of …

Ankur Sharma | 31 July 2026
Support

Hi! How can we help you today?

Loading…